1. Epigenetic therapy in MDS and acute AML: focus on decitabine

   • M. Lübbert
   • P. W. Wijermans

   Preface 17 November 2005 Pages: 1 - 2

2. Decitabine: a historical review of the development of an epigenetic drug

   • Dick de Vos
   • Wendy van Overveld

   Original Article 12 October 2005 Pages: 3 - 8

   

3. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients

   • P. W. Wijermans
   • M. Lübbert
   • A. Bosly

   Original Article 07 October 2005 Pages: 9 - 17

   

4. Clinical experience with decitabine in North American patients with myelodysplastic syndrome

   • Karen W. L. Yee
   • Elias Jabbour
   • Francis J. Giles

   Original Article 05 November 2005 Pages: 18 - 24

5. Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine

   • J. A. Pitako
   • P. S. Haas
   • M. Lübbert

   Original Article 16 November 2005 Pages: 25 - 31

6. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies

   • Björn Hackanson
   • Christian Robbel
   • Michael Lübbert

   Original Article 15 November 2005 Pages: 32 - 38

   

7. Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia

   • Oliver Galm
   • Stefan Wilop
   • Rainhardt Osieka

   Original Article 18 October 2005 Pages: 39 - 46

   

8. Decitabine activates specific caspases downstream of p73 in myeloid leukemia

   • Ingo Tamm
   • Mandy Wagner
   • Karin Schmelz

   Original Article 29 September 2005 Pages: 47 - 53

   

9. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts

   • Antonella Gozzini
   • Valeria Santini

   Original Article 15 October 2005 Pages: 54 - 60

   

10. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia

    • Andrea Kuendgen
    • Sabine Knipp
    • Norbert Gattermann

    Original Article 04 November 2005 Pages: 61 - 66

    

11. The hematopathological basis for studying effects of the demethylating agent 5-aza-2′-deoxycytidine (decitabine) in myelodysplasia

    • Hans Eckart Schaefer
    • Michael Lübbert

    Original Article 25 November 2005 Pages: 67 - 79